See the DrugPatentWatch profile for Fetzima
Fetzima (levomilnacipran) is not FDA-approved for pain management [1]. It is approved for the treatment of major depressive disorder (MDD) in adults [1].
What is Fetzima used for?
Fetzima is an extended-release capsule used to treat major depressive disorder (MDD) in adults [1]. It works by increasing the activity of norepinephrine and serotonin in the brain, neurotransmitters that are thought to play a role in mood regulation [2].
How does Fetzima work?
Fetzima is a serotonin-norepinephrine reuptake inhibitor (SNRI) [1]. It works by blocking the reabsorption of serotonin and norepinephrine in the brain. This increases the levels of these neurotransmitters available in the synaptic cleft, which can help to improve mood and reduce symptoms of depression [2].
What are the approved indications for Fetzima?
The only FDA-approved indication for Fetzima is for the treatment of major depressive disorder (MDD) in adults [1].
Are there any off-label uses for Fetzima?
While Fetzima is approved for MDD, healthcare providers may prescribe it for other conditions if they believe it is appropriate. However, information on off-label uses, such as for pain management, is not publicly available through official drug information channels. For a comprehensive understanding of potential uses, consulting a healthcare professional is recommended [2].
Where can I find information about Fetzima's patent status?
Information regarding Fetzima's patent status, including expiration dates and any ongoing patent litigation, can be found on DrugPatentWatch.com [3]. This resource provides detailed data on pharmaceutical patents.
Who makes Fetzima?
Fetzima is manufactured by AbbVie [1].
What are the common side effects of Fetzima?
Common side effects of Fetzima can include nausea, constipation, increased heart rate, increased sweating, insomnia, and decreased appetite [2].
What is the difference between Fetzima and other SNRIs?
Fetzima is a novel SNRI with a balanced inhibition of serotonin and norepinephrine reuptake. Other SNRIs, such as duloxetine and venlafaxine, also affect these neurotransmitters, but their specific profiles of inhibition and pharmacokinetics can differ, potentially leading to variations in efficacy and side effect profiles [2].
What clinical trials have been conducted for Fetzima?
Clinical trials for Fetzima have focused on its efficacy and safety in treating major depressive disorder. Information on specific trials, including data on patient populations and outcomes, can be found in the drug's prescribing information and in scientific literature [2].
What are the risks associated with Fetzima?
Fetzima carries risks, including a black box warning for increased suicidal thoughts and behaviors in children, adolescents, and young adults. Other risks can include serotonin syndrome, and potential for elevated blood pressure and heart rate [2].
Can Fetzima be used for chronic pain?
Fetzima is not FDA-approved for the treatment of chronic pain. While some SNRIs have been approved for certain pain conditions, Fetzima's approval is solely for major depressive disorder [1].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204118s000lbl.pdf
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/